Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
recombinant human growth hormone |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
159752-10-0
|
| gptkbp:category |
investigational drug
performance-enhancing drug (off-label use) |
| gptkbp:chemicalFormula |
C27H36N4O5S
|
| gptkbp:developedBy |
gptkb:Merck
|
| gptkbp:effect |
increases IGF-1 levels
increases growth hormone levels |
| gptkbp:hasSMILES |
CC(C)C(=O)N1CCC(CC1)NC(=O)C2=CC=CC=C2NC(=O)C3=CC=CC=C3S(=O)(=O)N
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ibutamoren
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
ghrelin receptor agonist
|
| gptkbp:molecularWeight |
528.7 g/mol
|
| gptkbp:otherName |
gptkb:MK-677
L-163,191 |
| gptkbp:PubChem_CID |
9846183
8021874 CHEMBL1214128 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
muscle pain
increased appetite transient edema increased fasting blood glucose mild insulin resistance |
| gptkbp:status |
not approved by FDA
not approved by EMA |
| gptkbp:UNII |
Q9Y2386G6E
|
| gptkbp:usedFor |
muscle wasting (investigational)
osteoporosis (investigational) treatment of growth hormone deficiency (investigational) |
| gptkbp:bfsParent |
gptkb:151096-09-2
gptkb:170729-80-3 |
| gptkbp:bfsLayer |
6
|